Cargando…

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients

Veliparib (ABT‐888) is a poly(ADP‐ribose) polymerase inhibitor in development for the treatment of high‐grade ovarian cancer or BRCA‐mutated breast cancer in combination with carboplatin and paclitaxel. The population pharmacokinetics of veliparib were characterized using combined data from 1470 adu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stodtmann, Sven, Nuthalapati, Silpa, Eckert, Doerthe, Kasichayanula, Sreeneeranj, Joshi, Rujuta, Bach, Bruce A., Mensing, Sven, Menon, Rajeev, Xiong, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Pharmacometrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453554/ https://www.ncbi.nlm.nih.gov/pubmed/33894017 http://dx.doi.org/10.1002/jcph.1875

Ejemplares similares

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
por: Lu, Yasong, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study
por: Kurosawa, Ken, et al.
Publicado: (2021)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
por: Wade, Janet R., et al.
Publicado: (2015)

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
por: Kotani, Naoki, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens
por: Tham, Lai San, et al.
Publicado: (2017)

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
por: Li, Hong, et al.
Publicado: (2017)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis
por: Li, Xiaohui, et al.
Publicado: (2018)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
por: Nguyen, Linh, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke
por: Tang, Fei, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling to Evaluate Standard Magnesium Sulfate Treatments and Alternative Dosing Regimens for Women With Preeclampsia
por: Du, Lihong, et al.
Publicado: (2018)

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses
por: Tamai, Toshiyuki, et al.
Publicado: (2017)

Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
por: Kielbasa, William, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
por: Scarpignato, Carmelo, et al.
Publicado: (2022)

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections
por: Chandorkar, Gurudatt, et al.
Publicado: (2015)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia
por: Zhang, Zufei, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System
por: Por, Elaine D., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014)

Population Pharmacokinetics and Exposure Response Assessment of CC‐292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia
por: Li, Yan, et al.
Publicado: (2017)

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development
por: Hanley, Michael J., et al.
Publicado: (2021)

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
por: Zhou, Xiaofei, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer
por: Zhang, Jason, et al.
Publicado: (2019)

A Target‐Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI‐62 in Healthy Adults
por: Wu, Nan, et al.
Publicado: (2021)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tqelil15ag8nnthgekmvjo2eku